Ferrous iron-dependent drug delivery enables controlled and selective release of therapeutic agents in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 45, 2013, Pages 18244-18249

  Deu, Edgar ^a,c   Chen, Ingrid T ^b   Lauterwasser, Erica M W ^b   Valderramos, Juan ^a   Li, Hao ^a   Edgington, Laura E ^a   Renslo, Adam R ^b   Bogyo, Matthew ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Combination therapy; Dipeptidyl peptidase; Iron mediated delivery; Targeted prodrugs

Indexed keywords

ANTIMALARIAL AGENT; DIPEPTIDYL AMINOPEPTIDASE INHIBITOR; DXL ML; FERROUS ION; HEMOGLOBIN; PEPTIDE HYDROLASE INHIBITOR; TRX; TRX ML; TRX MML; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CATABOLISM; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG TARGETING; DRUG TOLERABILITY; ERYTHROCYTE; FEMALE; HOST PARASITE INTERACTION; IC 50; IN VIVO STUDY; MOLECULAR PROBE; MOUSE; NONHUMAN; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PRIORITY JOURNAL; RODENT MALARIA;

COMBINATION THERAPY; DIPEPTIDYL PEPTIDASE; IRON-MEDIATED DELIVERY; TARGETED PRODRUGS;

ANIMALS; DELAYED-ACTION PREPARATIONS; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FERROUS COMPOUNDS; HETEROCYCLIC COMPOUNDS; MALARIA; MICE; PHOTOCHEMOTHERAPY; PLASMODIUM BERGHEI;

EID: 84887297993     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1312782110     Document Type: Article

References (35)

1. Hentze MW, Muckenthaler MU, Galy B, Camaschella C (2010) Two to tango: Regulation of Mammalian iron metabolism. Cell 142(1):24-38.
2. Kwok JC, Richardson DR (2002) The iron metabolism of neoplastic cells: Alterations that facilitate proliferation? Crit Rev Oncol Hematol 42(1):65-78.
3. Saletta F, Kovacevic Z, Richardson DR (2011) Iron chelation: Deciphering novel molecular targets for cancer therapy. The tip of the iceberg of a web of iron-regulated molecules. Future Med Chem 3(16):1983-1986.
4. Efferth T, et al. (2004) Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med 37(7):998-1009.
5. Toyokuni S (2009) Role of iron in carcinogenesis: Cancer as a ferrotoxic disease. Cancer Sci 100(1):9-16.
6. Richardson DR, Ponka P, Vyoral D (1996) Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: Examination of the intermediates involved in iron metabolism. Blood 87(8):3477-3488.
7. Ponka P (1997) Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood 89(1):1-25.
8. Li H, Child MA, Bogyo M (2012) Proteases as regulators of pathogenesis: Examples from the Apicomplexa. Biochim Biophys Acta 1824(1):177-185.
9. Sullivan DJ, Jr., Gluzman IY, Russell DG, Goldberg DE (1996) On the molecular mechanism of chloroquine's antimalarial action. Proc Natl Acad Sci USA 93(21):11865-11870.
10. Robert A, Benoit-Vical F, Meunier B (2005) The key role of heme to trigger the antimalarial activity of trioxanes. Coord Chem Rev 249(17-18):1927-1936.
11. Vennerstrom JL, et al. (2004) Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430(7002):900-904.
12. Valecha N, et al. (2010) Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: A phase II, multicenter, randomized, dose-finding clinical trial. Clin Infect Dis 51(6):684-691.
13. Moehrle JJ, et al. (2013) First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol 75(2):524-537.
14. Hartwig CL, et al. (2011) Investigating the antimalarial action of 1, 2, 4-trioxolanes with fluorescent chemical probes. J Med Chem 54(23):8207-8213.
15. Hartwig CL, et al. (2009) Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide-dependent. Biochem Pharmacol 77(3):322-336.
16. Fügi MA, Wittlin S, Dong Y, Vennerstrom JL (2010) Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals. Antimicrob Agents Chemother 54(3):1042-1046.
17. Creek DJ, et al. (2008) Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1, 2, 4-trioxolane antimalarials. Antimicrob Agents Chemother 52(4):1291-1296.
18. Mercer AE, et al. (2007) Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. J Biol Chem 282(13):9372-9382.
19. Eckstein-Ludwig U, et al. (2003) Artemisinins target the SERCA of Plasmodium falciparum. Nature 424(6951):957-961.
20. Haynes RK, et al. (2012) Interactions between artemisinins and other antimalarial drugs in relation to the cofactor model- A unifying proposal for drug action. ChemMedChem 7(12):2204-2226.
21. Tang Y, et al. (2005) Dispiro-1, 2, 4-trioxane analogues of a prototype dispiro-1, 2, 4- trioxolane: Mechanistic comparators for artemisinin in the context of reaction pathways with iron(II). J Org Chem 70(13):5103-5110.
22. O'Neill PM, et al. (2004) Design and synthesis of endoperoxide antimalarial prodrug models. Angew Chem Int Ed Engl 43(32):4193-4197.
23. Klemba M, Gluzman I, Goldberg DE (2004) A Plasmodium falciparum dipeptidyl aminopeptidase I participates in vacuolar hemoglobin degradation. J Biol Chem 279(41):43000-43007.
24. Deu E, et al. (2010) Functional studies of Plasmodium falciparum dipeptidyl aminopeptidase I using small molecule inhibitors and active site probes. Chem Biol 17(8):808-819.
25. Arastu-Kapur S, et al. (2008) Identification of proteases that regulate erythrocyte rupture by the malaria parasite Plasmodium falciparum. Nat Chem Biol 4(3):203-213.
26. Mahajan SS, Gut J, Rosenthal PJ, Renslo AR (2012) Ferrous iron-dependent delivery of therapeutic agents to the malaria parasite. Future Med Chem 4(18):2241-2249.
27. Mahajan SS, et al. (2011) A fragmenting hybrid approach for targeted delivery of multiple therapeutic agents to the malaria parasite. ChemMedChem 6(3):415-419.
28. Yuan F, Verhelst SH, Blum G, Coussens LM, Bogyo M (2006) A selective activity-based probe for the papain family cysteine protease dipeptidyl peptidase I/cathepsin C. J Am Chem Soc 128(17):5616-5617.
29. Deu E, Yang Z, Wang F, Klemba M, Bogyo M (2010) Use of activity-based probes to develop high throughput screening assays that can be performed in complex cell extracts. PLoS ONE 5(8):e11985.
30. Denny WA (2004) Tumor-activated prodrugs- A new approach to cancer therapy. Cancer Invest 22(4):604-619.
31. Creek DJ, et al. (2007) Iron-mediated degradation kinetics of substituted dispiro-1, 2, 4- trioxolane antimalarials. J Pharm Sci 96(11):2945-2956.
32. Santi DV, Schneider EL, Reid R, Robinson L, Ashley GW (2012) Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates. Proc Natl Acad Sci USA 109(16):6211-6216.
33. Ashley GW, Henise J, Reid R, Santi DV (2013) Hydrogel drug delivery system with predictable and tunable drug release and degradation rates. Proc Natl Acad Sci USA 110(6):2318-2323.
34. Verdoes M, et al. (2012) A nonpeptidic cathepsin S activity-based probe for noninvasive optical imaging of tumor-associated macrophages. Chem Biol 19(5):619-628.
35. Paulick MG, Bogyo M (2011) Development of activity-based probes for cathepsin X. ACS Chem Biol 6(6):563-572.